Korean J Med.  2016 Dec;91(3):250-256. 10.3904/kjm.2016.91.3.350.

New COX-2 Inhibitors

• Kim D
• Sung YK

• KMID: 2361428
• DOI: http://doi.org/10.3904/kjm.2016.91.3.350

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation. There are two kinds of NSAID classified according to the selectivity of COX-2 inhibition: non-selective NSAIDs and cyclooxygenase (COX)-2 inhibitors. Non-selective NSAIDs have a high incidence of gastrointestinal and bleeding-associated adverse events, while COX-2 inhibitors are safer in terms of these events. However, COX-2 inhibitors are thought to cause increased cardiovascular events. The COX-2 inhibitors rofecoxib and valdecoxib were withdrawn from the market over safety concerns. Three COX-2 inhibitors are now available in South Korea after the recent approval of etoricoxib and polmacoxib for osteoarthritis patients. After reviewing the history of and recent studies about the safety of COX-2 inhibitors, physicians should find new uses for old drugs.

Keyword

Anti-inflammatory agents, Non-steroidal; Cyclooxygenase inhibitors; Safety

MeSH Terms

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors*
Cyclooxygenase Inhibitors
Humans
Incidence
Inflammation
Korea
Osteoarthritis
Prostaglandin-Endoperoxide Synthases
Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Prostaglandin-Endoperoxide Synthases